Akili’s EndeavorRx Receives the US FDA’s Approval as the First Game-Based Digital Therapeutic to Improve Attention Function in Children with ADHD

 Akili’s EndeavorRx Receives the US FDA’s Approval as the First Game-Based Digital Therapeutic to Improve Attention Function in Children with ADHD

Akili’s EndeavorRx Receives the US FDA’s Approval as the First Game-Based Digital Therapeutic to Improve Attention Function in Children with ADHD

Shots:

  • The FDA’s De novo clearance is based on five clinical studies in 600+ children diagnosed with ADHD, which demonstrated an improved measure of attention. After 4wks., one-third of children had no longer measurable attention deficit on at least one measure of objective attention
  • Change in child’s day-to-day impairments following @1mos. treatment with EndeavorRx which increased to 68% after 2nd month of treatment. Improvements in ADHD impairments following a month of treatment were maintained for up to a month
  • EndeavorRx is indicated for pediatric patients aged 8-12 yrs. with primarily inattentive or combined-type ADHD who have demonstrated an attention issue and will be available with a prescription. The digital therapeutics can be downloaded from the App Store on their mobile devices and does not require any additional equipment

Click here to read full press release/ article | Ref: Akili Therapeutics | Image: Akili Therapeutics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post